C4 Therapeutics Announces Strategic Discovery Research Collaboration With Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
C4 Therapeutics Announces Strategic Discovery Research Collaboration With Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline
合作側重於C4T內部發現管道中的兩種靶向蛋白質降解劑
C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration
C4T將獲得1,600萬美元的預付款;位於德國達姆施塔特的默沙東KGaA將支付合作下的探索研究費用n
C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration
C4T有資格在整個合作中獲得高達約7.4億美元的發現、開發和商業里程碑款項,以及未來的特許權使用費
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.
馬薩諸塞州沃特敦,2024年3月4日(GLOBE NEWSWIRE)——致力於推進靶向蛋白降解科學的臨床階段生物製藥公司C4 Therapeutics, Inc.(C4T)(納斯達克股票代碼:CCCC)今天宣佈已與位於德國達姆施塔特的默沙東KGaA簽訂了許可和合作協議,後者在美國以EMD Serono的名義經營醫療業務和加拿大,將獨家發現兩種針對關鍵致癌蛋白的靶向蛋白質降解劑,C4T已在其內部發現計劃中取得了進展。
"We look forward to partnering with Merck KGaA, Darmstadt, Germany, and leveraging our collective strengths to advance an exciting program from C4T's internal oncology pipeline that has the potential to transform how cancer is treated," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "This new partnership highlights C4T's differentiated approach to targeted protein degradation science and our strong track record of designing novel targeted protein degrader medicines with desirable drug-like properties that have the potential to treat patients with unmet medical needs."
C4 Therapeutics總裁兼首席執行官安德魯·赫希表示:“我們期待與德國達姆施塔特的默沙東KGaA合作,利用我們的集體優勢,推進C4T內科腫瘤學產品線中一項激動人心的項目,該項目有可能改變癌症的治療方式。”“這項新的合作伙伴關係凸顯了C4T的差異化靶向蛋白質降解科學方法,以及我們在設計具有理想的類藥物特性的新型靶向蛋白質降解藥物方面的良好記錄,這些藥物有可能治療醫療需求未得到滿足的患者。”
"The collaboration adds to Merck KGaA, Darmstadt, Germany's growing portfolio of targeted protein degradation projects and accelerates our efforts to expand our presence in this highly dynamic field," said Paul Lyne, Head of Research Unit Oncology at the Healthcare business sector of Merck KGaA, Darmstadt, Germany. "We look forward to capitalizing on C4 Therapeutics' experience in advancing degrader candidates targeting disease-causing proteins from discovery to the clinical stage, with the shared goal of improving patient outcomes."
德國達姆施塔特默沙東KGaA醫療業務部門腫瘤學研究部負責人保羅·萊恩說:“此次合作增加了德國達姆施塔特默沙東KGaA不斷增長的靶向蛋白降解項目組合,並加快了我們在這個高度動態領域的影響力。”“我們期待利用C4 Therapeutics在將靶向致病蛋白的降解候選藥物從發現階段推進到臨床階段方面的經驗,共同目標是改善患者的預後。”
Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany, will collaborate to discover two targeted protein degraders against critical oncogenic proteins. C4T will receive an upfront payment of $16 million. Merck KGaA Darmstadt, Germany, will fund C4T's discovery research efforts. C4T has the potential to receive up to approximately $740 million in discovery, regulatory, and commercial milestone payments across the collaboration. In addition, C4T is eligible for mid-single to low-double digit tiered royalties on future sales for each program.
根據協議條款,C4T和德國達姆施塔特的默沙東KGaA將合作發現兩種針對關鍵致癌蛋白的靶向蛋白降解劑。C4T將獲得1,600萬美元的預付款。德國達姆施塔特默沙東KGaA將資助C4T的發現研究工作。在整個合作過程中,C4T有可能獲得高達約7.4億美元的發現、監管和商業里程碑付款。此外,C4T有資格在每個計劃的未來銷售中獲得中等至低兩位數的分級特許權使用費。
As part of the collaboration, C4T will utilize its proprietary TORPEDO platform to discover degraders targeting the partnership's oncogenic proteins of interest. Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.
作爲合作的一部分,C4T將使用其專有的魚雷 該平台可發現針對合作伙伴關係中感興趣的致癌蛋白的降解劑。位於德國達姆施塔特的默沙東KGaA將負責這些項目的候選藥物的臨床開發和商業化。
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
關於 C4 療法
C4 Therapeutics(C4T)(納斯達克股票代碼:CCCC)是一家臨床階段的生物製藥公司,致力於兌現靶向蛋白質降解科學的承諾,創造改變患者生活的新一代藥物。C4T正在通過臨床研究和利用其TORPEDO推進靶向腫瘤學項目 該平台可高效設計和優化小分子藥物,以解決難以治療的疾病。C4T的降解劑藥物旨在利用人體的天然蛋白質回收系統快速降解致病蛋白,從而有可能克服耐藥性、不可藥物靶標和改善患者預後。欲了解更多信息,請訪問 www.c4therapeutics。
Forward-Looking Statements
This press release contains "forward-looking statements" of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO platform in the development of novel, selective, orally bioavailable BiDAC and MonoDAC degraders; our ability to achieve potential future milestone or royalty payments; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of the risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in C4 Therapeutics' most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and C4 Therapeutics undertakes no duty to update this information unless required by law.
前瞻性陳述
本新聞稿包含1995年《私人證券訴訟改革法》所指的C4 Therapeutics, Inc.的 “前瞻性陳述”。這些前瞻性陳述可能包括但不限於關於我們爲患者開發潛在療法的能力的明示或暗示陳述;我們的治療方法的設計和潛在療效;我們的 TORPEDO 的預測能力 開發新型、選擇性、口服生物利用的bidac和monoDAC降解劑的平台;我們實現未來潛在里程碑或特許權使用費付款的能力;以及我們爲未來運營提供資金的能力。本新聞稿中的任何前瞻性陳述均基於管理層當前對未來事件的預期和信念,並存在許多風險和不確定性,這些風險和不確定性可能導致實際業績與此類前瞻性陳述中列出或暗示的業績存在重大不利差異。有關風險和不確定性以及其他重要因素的討論,其中任何一個都可能導致我們的實際業績與前瞻性陳述中包含的有所不同,請參閱C4 Therapeutics向美國證券交易委員會提交的最新10-K表年度報告和/或10-Q表季度報告中題爲 “風險因素” 的章節。本新聞稿中的所有信息均截至發佈之日,除非法律要求,否則C4 Therapeutics沒有義務更新這些信息。
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
聯繫人:
投資者:
考特尼·索爾伯格
投資者關係高級經理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒體:
Loraine Spreen
企業傳播與患者宣傳高級董事
LSpreen@c4therapeutics.com